Release Date: 31 March 2023
Bispecific antibodies have transformed the landscape of cancer treatment in the last decade, with as many as 10 bispecific antibodies having gained approval in different parts of the world in the last 8 years. Out of all ...
Release Date: 27 March 2023
The use of the body’s immune system to fight diseases like cancer has emerged as a promising strategy, which is being wholly exploited by researchers and drug makers, especially since the advent of targeted therapy....
Release Date: 23 March 2023
One of the most revolutionary developments in the drug development process was the creation of proprietary technical platforms, which have substantially facilitated and simplified the identification and manufacture of pha...
Release Date: 23 March 2023
In recent years, multispecific antibodies have caused waves in the drug research and development domain for having properties that surpass that of monoclonal antibodies. Tetraspecific antibodies have become the newest kin...
Release Date: 28 February 2023
The development of cell therapies has significantly changed the approaches to treating conditions like cancer, autoimmune disorders, infectious diseases, and tissue regeneration, among many others. Continuous advancements...
Release Date: 27 February 2023
Neuroendocrine tumors, such as small-cell lung cancer, have a high relapse rate, few treatment options, and a dismal prognosis. Chemotherapy, targeted therapy, and immune therapy are among the available treatments; howeve...
Release Date: 27 February 2023
The PARP protein participates in a number of cellular proteins including DNA repair, modification and transcription, among some others, and its inhibition was suggested as a promising treatment opportunity for several can...
Release Date: 24 February 2023
Protein folding is an important event in making a polypeptide chain functional for biological use. The biologically active version of the protein is in its native 3D shape, which is attained with the aid of many chaperone...
Release Date: 23 February 2023
Immune checkpoint inhibitors have been the major reason of success for immunotherapy. With PD-1 and CTLA-4 immune checkpoint inhibitors showing robust response rates both in the patient segment and the commercial segment,...
Release Date: 23 February 2023
The process of drug delivery and development is filled with high-risk and stakes with a course of long and costly timelines. Despite these pitiable probabilities, the possibility of driving and leading a billion dollar ma...
Release Date: 23 February 2023
For over a long period of time, immune checkpoint inhibitors have been dominating the landscape of cancer immunotherapy. CTLA-4 and PD-1/PDL-1 inhibitors have seen a lot of advancement in recent years, however, despite th...
Release Date: 22 February 2023
Over the past ten years, immunotherapy has transformed the way cancer is treated by delivering impressive and long-lasting responses in patients with a wide range of tumor types. It is now considered as the fourth pillar ...
Release Date: 21 February 2023
Over the past decade, the introduction of immunotherapy in the field of cancer has significantly changed the treatment paradigm. The substantial progress in the understanding of how the tumor invades the immune system has...
Release Date: 20 February 2023
Immunotherapy has been revolutionizing the landscape of cancer treatment. It has been over a decade since this therapeutic approach was first introduced and since then, the extraordinary extent of investments indicates th...
Release Date: 17 February 2023
Antibody drug conjugates have become the fastest growing drug class in the global pharmaceutical market. Combining the targeting ability of a monoclonal activity with the cytotoxic action of anti-cancer drugs in one molec...